Preprint Review Version 1 This version is not peer-reviewed

Recombinant Live-Attenuated Salmonella Vaccine for Veterinary Use

Version 1 : Received: 17 October 2024 / Approved: 17 October 2024 / Online: 18 October 2024 (08:23:18 CEST)

How to cite: Chagas, D. B.; Santos, F. D. S.; de Oliveira, N. R.; Bohn, T. L. O.; Dellagostin, O. A. Recombinant Live-Attenuated Salmonella Vaccine for Veterinary Use. Preprints 2024, 2024101420. https://doi.org/10.20944/preprints202410.1420.v1 Chagas, D. B.; Santos, F. D. S.; de Oliveira, N. R.; Bohn, T. L. O.; Dellagostin, O. A. Recombinant Live-Attenuated Salmonella Vaccine for Veterinary Use. Preprints 2024, 2024101420. https://doi.org/10.20944/preprints202410.1420.v1

Abstract

Vaccination is essential in maintaining animal health, with a priority on safety and cost-effectiveness in veterinary vaccines. The development of recombinant live-attenuated Salmonella vaccines (RASVs) has enabled the construction of balanced lethal systems, ensuring the stability of plasmid vectors encoding protective antigens post-immunization. These vaccines are particularly suitable for production animals, providing long-term immunity against a range of bacterial, viral, and parasitic pathogens. This review summarizes the progress made in this field, with a focus on clinical trials demonstrating the efficacy and commercial potential of RASVs in veterinary medicine.

Keywords

vaccine development; Salmonella; attenuation; RASV; animal

Subject

Biology and Life Sciences, Immunology and Microbiology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.